Zin Myint is an Oncology physician affiliated with University of Kentucky. OpenAlex indexes 154 publications with 1,424 citations (h-index 17); ClinicalTrials.gov lists 6 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
800 Rose St
Lexington, KY 405360093
Telephone
859-257-4488Provider last certified this registry record 20 Nov 2025.
Clinical trials
- Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones
Sponsor: National Cancer Institute (NCI)
- Impact of Daily Oral Cannabis Doses in Patients With Cancer
Sponsor: Shanna Babalonis, PhD
- Pembro With Radiation With or Without Olaparib
Sponsor: Zin W Myint
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Bayer Healthcare Pharmaceuticals Inc.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Exelixis Inc.Program year202410 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
62.4%Gonadotropin Releasing Hormone Receptor Antagonist16.6%Orgovyx100%Part D≥51 patientsCytochrome P450 17A1 Inhibitor13.2%Abiraterone Acetate92%Zytiga9%Part D<11 patients+ 4 more classes in this area
Metabolism & gastrointestinal
16.4%Corticosteroid13.7%Prednisone100%Part D≥47 patientsSerotonin-3 Receptor Antagonist1.3%Ondansetron Odt55%Ondansetron Hcl45%Part D<11 patients+ 2 more classes in this area
Nervous system
11.8%Opioid Agonist5.4%Oxycodone Hcl91%Morphine Sulfate Er9%Part D<11 patientsPhenothiazine3.7%Prochlorperazine Maleate100%Part D≥45 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study
Cancer Immunology Immunotherapy
2025 - Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study
Cancer Immunology Immunotherapy
2025 - Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study
European Urology Oncology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
David Moliterno, MD
University of Kentucky
Robert Dipaola
University of Kentucky
Darwin Conwell, MD
University of Kentucky
Phillip Tibbs
University of Kentucky
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”